Literature DB >> 26703054

Elevator Muscle Anterior Resection: A New Technique for Blepharoptosis.

Gian Luigi Zigiotti1, Gabriele Delia, Pierluigi Grenga, Francesco Pichi, Miguel Rechichi, Mahmoud O Jaroudi, Francesco Stagno d'Alcontres, Flavia Lupo, Alessandro Meduri.   

Abstract

Blepharoptosis is a condition of inadequate upper eyelid position, with a downward displacement of the upper eyelid margin resulting in obstruction of the superior visual field. Levator resection is an effective technique that is routinely used to correct aponeurotic ptosis. The anterior levator resection is the procedure of choice in moderate blepharoptosis when there is moderate to good levator muscle function, furthermore, with an anterior approach, a greater resection can be achieved than by a conjunctival approach. The authors describe a modification in the Putterman technique with a resection done over a plicated elevator, plication that was suggested by Mustardè. The technique has been named as elevator muscle anterior resection. The elevator muscle anterior resection inspires from the Fasanella-Servat operation by the use of a clamp, making the operation simple and predictable.

Entities:  

Mesh:

Year:  2016        PMID: 26703054     DOI: 10.1097/SCS.0000000000002290

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  3 in total

1.  Management of Senile Ptosis with Levator Muscle Resection Using the Putterman Clamp.

Authors:  Ju-Wen Yang
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-06-01

2.  Case Report: Botulinum Toxin-A for Complication of Exposure Keratopathy Following Frontalis-Orbicularis Oculi Muscle Flap Shortening.

Authors:  Chun-Chieh Lai; Chia-Chen Lin
Journal:  Front Med (Lausanne)       Date:  2022-04-13

3.  Mild to moderate blepharoptosis correction: Outcomes of levator aponeurosis posterior layer plication.

Authors:  Er Pan; Wen-Li Chen; Sheng-Chang Zhang; Yi Chen; Jian-Gang Yu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.